awmsg logo



enoxaparin (Clexane®)


Reference No. 125

Publication date:
01/06/2010


Appraisal information

enoxaparin (Clexane®) solution for injection


Company: Sanofi-Aventis Ltd
BNF category: Cardiovascular system
NMG meeting date: 17/03/2010
AWMSG meeting date: 28/04/2010
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 0610
Ministerial ratification: 28/05/2010

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Enoxaparin (Clexane®) is recommended as an option for use within NHS Wales for the treatment of acute ST-segment elevation myocardial infarction (STEMI). AWMSG is of the opinion that enoxaparin (Clexane®) is not suitable for shared care within NHS Wales.
Final Appraisal Recommendation (FAR)
Download